U.S. market Closed. Opens in 10 hours 7 minutes

TCBP | TC Biopharm (Holdings) Plc Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 0.4013 - 0.4759
52 Week Range 0.3487 - 26.16
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 1,236,771
Average Volume 2,320,392
Shares Outstanding 494,513
Market Cap 4,114,350
Sector Healthcare
Industry Biotechnology
IPO Date 2022-02-11
Valuation
Profitability
Growth
Health
P/E Ratio N/A
Forward P/E Ratio N/A
EPS -230.62
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 41
Country UK
Website TCBP
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
*Chart delayed
Analyzing fundamentals for TCBP we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see TCBP Fundamentals page.

Watching at TCBP technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on TCBP Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙